to share voting and dispositive power over the shares held by such entities. The address for Vivo is 505 Hamilton Avenue, Suite 207, Palo Alto, California 94301.
(5)
Shares beneficially owned by Mr. Melo include (i) 525,000 restricted stock units, all of which were unvested as of June 15, 2020, and (ii) 138,071 shares of Common Stock issuable upon exercise of stock options that were exercisable within 60 days of June 15, 2020.
(6)
Shares beneficially owned by Mr. Doerr include (i) 67,268,358 shares of Common Stock beneficially owned by Foris, in which Mr. Doerr indirectly owns all of the membership interests, (ii) 567 shares of Common Stock held by The Vallejo Ventures Trust U/T/A 2/12/96, of which Mr. Doerr is a trustee, (iii) 278,882 shares of Common Stock held by entities affiliated with Kleiner Perkins Caufield & Byers of which Mr. Doerr is an affiliate, excluding 16,399 shares over which Mr. Doerr has no voting or investment power, (iv) 2,266 restricted stock units, all of which were unvested as of June 15, 2020, and (v) 10,265 shares of Common Stock issuable upon exercise of stock options that were exercisable within 60 days of June 15, 2020.
(7)
Shares beneficially owned by Dr. Duyk include (i) 9,566 restricted stock units, all of which were unvested as of June 15, 2020, and (ii) 4,666 shares of Common Stock issuable upon exercise of stock options that were exercisable within 60 days of June 15, 2020.
(8)
Shares beneficially owned by Mr. Eykerman include (i) 2,266 restricted stock units, all of which were unvested as of June 15, 2020, and (ii) 8,199 shares of Common Stock issuable upon exercise of stock options that were exercisable within 60 days of June 15, 2020. Mr. Eykerman was appointed to the Board on May 18, 2017 as the designee of DSM. Mr. Eykerman disclaims beneficial ownership of all shares of Amyris Common Stock that are or may be beneficially owned by DSM or any of its affiliates.
(9)
Mr. Goppelsroeder was appointed to the Board on November 2, 2017 as the designee of DSM. Mr. Goppelsroeder does not beneficially own any shares of Amyris Common Stock directly and disclaims beneficial ownership of all shares of Amyris Common Stock that are or may be beneficially owned by DSM or any of its affiliates.
(10)
Shares beneficially owned by Dr. Kung include (i) 13,347,068 shares of Common Stock beneficially owned by Vivo, over which Dr. Kung may be deemed to share voting and dispositive power, (ii) 2,932 restricted stock units, all of which were unvested as of June 15, 2020 and (iii) 6,216 shares of Common Stock issuable upon exercise of stock options that were exercisable within 60 days of June 15, 2020. Dr. Kung was appointed to the Board on November 2, 2017 as the designee of Vivo. Dr. Kung disclaims beneficial ownership over shares of Amyris Common Stock that are or may be beneficially owned by Vivo except to the extent of his pecuniary interest therein.
(11)
Shares beneficially owned by Mr. McCann include (i) 2,266 restricted stock units, all of which were unvested as of June 15, 2020, and (ii) 750 shares of Common Stock issuable upon exercise of stock options that were exercisable within 60 days of June 15, 2020.
(12)
Shares beneficially owned by Mr. Mills include (i) 2,266 restricted stock units, all of which were unvested as of June 15, 2020, and (ii) 3,466 shares of Common Stock issuable upon exercise of stock options that were exercisable within 60 days of June 15, 2020.
(13)
Shares beneficially owned by Ms. Piwnica include (i) 5,758,835 shares beneficially owned by Naxyris S.A. (“Naxyris”), over which Ms. Piwnica may be deemed to share voting and dispositive power, (ii) 2,266 restricted stock units, all of which were unvested as of June 15, 2020, and (iii) 10,265 shares of Common Stock issuable upon exercise of stock options that were exercisable within 60 days of June 15, 2020. Ms. Piwnica was designated to serve as a director by Naxyris. Ms. Piwnica indirectly owns 100% of Naxyris, through its affiliate Arianna S.A.
(14)
Shares beneficially owned by Dr. Yang include (i) 2,266 restricted stock units, all of which were unvested as of June 15, 2020, and (ii) 9,065 shares of Common Stock issuable upon exercise of stock options that were exercisable within 60 days of June 15, 2020.
(15)
Shares beneficially owned by Mr. Alvarez include 30,000 shares of Common Stock issuable upon exercise of stock options that were exercisable within 60 days of June 15, 2020.
(16)
Shares beneficially owned by Ms. Kelsey include (i) 40,333 restricted stock units, all of which were unvested as of June 15, 2020, and (ii) 35,625 shares of Common Stock issuable upon exercise of stock options that were exercisable within 60 days of June 15, 2020.